• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Am J Transplant. First case of COVID-19 in a kidney transplant recipient treated with belatacept

tetano

Editor, Senior Moderator
Am J Transplant. 2020 Apr 13. doi: 10.1111/ajt.15919. [Epub ahead of print]
First case of COVID-19 in a kidney transplant recipient treated with belatacept.


Marx D[SUP]1[/SUP], Moulin B[SUP]1[/SUP], Fafi-Kremer S[SUP]2[/SUP], Benotmane I[SUP]1,[/SUP][SUP]2[/SUP], Gautier G[SUP]1[/SUP], Perrin P[SUP]1[/SUP], Caillard S[SUP]1[/SUP].

Author information




Abstract

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing public health emergency of international concern. Acute respiratory distress syndrome (ARDS) develops in 3-30% of patients with COVID-19 (1,2), because of direct virus-induced cytopathic effects in the respiratory tract or cytokine storms triggered by the host's immune response. Comorbidities are known to increase the risk of ARDS in SARS-CoV-2-infected patients (1).
This article is protected by copyright. All rights reserved.



PMID:32282977DOI:10.1111/ajt.15919
 
Back
Top Bottom